CD147 (Basigin/EMMPRIN), a multifunctional member of the immunoglobulin superfamily (IgSF), is a critical regulator of tumor progression, immune modulation, and metabolic adaptation.
First-pass extracted concept
CD147/Basigin/EMMPRIN
Candidate: concept label1 source documents7 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
Basigin, CD147, EMMPRIN
Evidence Snippets
Supporting Sources
Linked Claims
CD147 functions as an independent prognostic biomarker in multiple malignancies.
CD147/Basigin/EMMPRIN is a critical regulator of tumor progression, immune modulation, and metabolic adaptation.
Under physiological conditions, CD147 acts as a dynamic scaffold interacting with monocarboxylate transporters, integrins, and cyclophilin A.
CD147 acts as an Energy-Structure Coupler that coordinates metabolic flux via monocarboxylate transporters with morphogenetic plasticity via integrins and matrix metalloproteinases.
CD147 is exploited as an entry receptor for pathogens including SARS-CoV-2, HIV-1, and Plasmodium falciparum.
Pathological overexpression of CD147 induces matrix metalloproteinase secretion, epithelial-mesenchymal transition, metabolic reprogramming, and immune evasion.
The review proposes emerging strategies to exploit CD147 as a precision biomarker and therapeutic target across diverse diseases.